The approval was based on data from the phase 3 COSMIC-311 study. The Food and Drug Administration has approved Cabometyx ® (cabozantinib) for the treatment of patients 12 years of age and older ...

Treatment with Cabometyx in combination with Tecentriq induced superior progression-free survival outcomes and disease control rates versus Nexavar alone in patients with advanced hepatocellular ...

In the CheckMate -9ER trial, OS (overall survival) benefits were maintained at over three-years of follow-up. 1 Median OS was significantly higher for patients on Cabometyx in combination with ...

Exelixis is pursuing an additional approval for Cabometyx in neuroendocrine tumors. The U.S. FDA has assigned an action date of April 3, 2025 for the supplemental New Drug Application. In a ...

In August, the FDA accepted Exelixis’ (NASDAQ:EXEL) request for Cabometyx label expansion, granting Apr. 3 as the target action date. The sNDA focused on adults with previously treated advanced ...

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved a label expansion for its best-selling cancer therapy Cabometyx (cabozantinib) to include patients aged 12 years of age and ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs. The phase 3 CABINET trial demonstrated that Cabometyx ...

PARIS, FRANCE, 2 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx ...